ArticleFrontiers in oncology2021
Safranal Inhibits Angiogenesis
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms.European journal of medical research · 2025Pooled it
- Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities (Review).International journal of molecular medicine · 2024Pooled it
- Phytochemical profile, antioxidant, antimicrobial activity, antibiofilm, cytotoxicity, and HR-LCMS of Tribulus terrestris.Journal, genetic engineering & biotechnology · 2026Article
- Redox-mediated activation of PI3K/PTEN pathways by A. baumannii OMV-V. myrtillus conjugate in pancreatic cancer cells.Archives of microbiology · 2026Article
- Vascular endothelial growth factor (VEGF)-related blood flow regulation and anti-inflammation in the protection of Danzhu Fuyuan Granules against cognitive impairment.Metabolic brain disease · 2026Article
- Oroxylin A FromCanadian respiratory journal · 2026Article
- Protective Effects of Safranal Against Spike Protein-Induced Mitochondrial Dysfunction and Inflammation in Peripheral and Central Immune Cells.Current developments in nutrition · 2026Article
- A therapeutic approach of LC-MS characterised MFER-Mc against alcohol and NDEA induced hepatocellular carcinoma activity through LXR-α, LXR-β and HMG-CoA pathway: an in-silico, in-vitro and in-vivo study.Medical oncology (Northwood, London, England) · 2025Article
- Evaluation of the effects of Theranekron and Sorafenib treatments on alpha-fetoprotein, heat shock protein 90 alpha and indoleamine 2,3 dioxygenase 1 enzyme levels in experimental hepatocellular carcinoma in rats.Molecular biology reports · 2025Article
- Study the impact ofCytotechnology · 2025Article
- Granzyme B Promotes Proliferation, Migration and EMT Process in Gastric Cancer.Biochemical genetics · 2025Article
- Regulation and Crosstalk of Cells and Factors in the Pancreatic Cancer Microenvironment.Current cancer drug targets · 2025Review
- Effect ofIranian journal of basic medical sciences · 2025Review
- Exosomal CircRNAs: A Future Star in Colorectal Cancer.Current cancer drug targets · 2025Review
- Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment.Recent patents on anti-cancer drug discovery · 2025Article
- In vitro and in vivo evaluation of the diabetic wound healing properties of Saffron (Crocus Sativus L.) petals.Scientific reports · 2024Article
- Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy.Current cancer drug targets · 2024Review
- LARP1 knockdown inhibits cultured gastric carcinoma cell cycle progression and metastatic behavior.Open life sciences · 2024Article
- Transcription Factor MAZ Potentiates the Upregulated NEIL3-mediated Aerobic Glycolysis, thereby Promoting Angiogenesis in Hepatocellular Carcinoma.Current cancer drug targets · 2024Article
- Ferroptosis is Involved in the Pharmacological Effect of Ginsenoside.Mini reviews in medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nature has a nearly infinite inventory of unexplored phytochemicals and biomolecules that have the potential to treat a variety of diseases. Safranal exhibits anti-cancer property and the present study explores its antiangiogenic property. Hepatocellular carcinoma (HCC) ranks as the sixth deadliest among all cancer types. Targeting the non-tumor vasculature supporting system is very promising as it has less plasticity, unlike malignant cells that are often associated with issues like drug resistance, poor prognosis, and relapse. In this study, we successfully inhibited the proliferation of primary human umbilical vein endothelial cells (HUVEC) with an IC50 of 300μM and blocked VEGF secretion in HepG2 cells. Furthermore, safranal inhibited VEGF-induced angiogenesis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.